Okutucu Murat, Fındık Hüseyin, Arslan Mehmet Gökhan
a Department of Opthalmology , Recep Tayyip Erdoğan Üniversitesi Zihni Derin Yerleşkesi , Rize , Turkey.
Cutan Ocul Toxicol. 2019 Jun;38(2):196-200. doi: 10.1080/15569527.2019.1575390. Epub 2019 Mar 1.
To investigate the acute effects of brinzolamide, betaxolol, and latanoprost (drugs commonly used in the medical management of glaucoma) on choroidal thickness using enhanced depth imaging optical coherence tomography (EDI-OCT).
Ninety healthy volunteers were evaluated in this prospective study. Participants were randomly divided into 3 groups. Brinzolamide, betaxolol, and latanoprost were administered into the left eyes of the first group (n = 30), second group (n = 30), and third group (n = 30), respectively, and artificial tear (Sodium hyaluronate) was instilled into the right eyes of all participants. Subfoveal choroidal thickness (SFCT) was measured using EDI-OCT before and 45 minutes after administration of the antiglaucomatous drops.
SFCT revealed a significant increase in the left eye (administered antiglaucomatous drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.049) and a significant increase also in the right eye (administered artificial drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.001). However, SFCT did not reveal a significant increase in the left eye (p = 0.213) or in the right eye (p = 0.062) in the latanoprost group.
Brinzolamide and betaxolol caused an increase in SFCT, while latanoprost had no significant effect on SFCT.
使用增强深度成像光学相干断层扫描（EDI-OCT）研究布林佐胺、倍他洛尔和拉坦前列素（青光眼治疗常用药物）对脉络膜厚度的急性影响。
在这项前瞻性研究中评估了90名健康志愿者。参与者被随机分为3组。布林佐胺、倍他洛尔和拉坦前列素分别滴入第一组（n = 30）、第二组（n = 30）和第三组（n = 30）的左眼，所有参与者的右眼滴入人工泪液（透明质酸钠）。在滴入抗青光眼滴眼液前及滴入后45分钟，使用EDI-OCT测量黄斑中心凹下脉络膜厚度（SFCT）。
SFCT显示，布林佐胺组（p = 0.001）和倍他洛尔组（p = 0.049）的左眼（滴入抗青光眼滴眼液）以及布林佐胺组（p = 0.001）和倍他洛尔组（p = 0.001）的右眼（滴入人工泪液）均有显著增加。然而，拉坦前列素组的左眼（p = 0.213）和右眼（p = 0.062）的SFCT均未显示出显著增加。
布林佐胺和倍他洛尔可导致SFCT增加，而拉坦前列素对SFCT无显著影响。
